Pentixapharm Holding AG

Pentixapharm Holding AG is a clinical-stage biopharmaceutical company specializing in the development of radiopharmaceuticals. It focuses on CXCR4 ligand-based technologies for theranostic applications, combining diagnosis and therapy in hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. Key products include PentixaFor (PT-001), a Gallium-68 tracer in Phase III for diagnosing tumors, primary aldosteronism, and other disorders; PentixaTher (PT-002), a Yttrium-90 and Lutetium-177 therapeutic in Phase 1/2 for leukemia; and anti-GlycoTarget antibodies for solid tumors. The pipeline features additional oncology candidates like PT-00X and GT-series compounds. Founded in 2019 as a spin-off from Eckert & Ziegler Group and headquartered in Berlin and Würzburg, Germany, the company employs 80 experts from leading institutions, driving innovation with over 20 investigator-initiated studies and compounds tested in more than 2,000 patients. Pentixapharm Holding AG plays a significant role in the expanding radiopharmaceutical market through its first-in-class approaches.